Dr. Baltazar   Gomez-Mancilla
My Social Links

Dr. Baltazar Gomez-Mancilla

Associate Professor
Novartis Institute Biological Research, Basel, Switzerland


Highest Degree
Ph.D. in Neurobiology from Laval University, Canada

Share this Profile

Area of Interest:

Biomedical Sciences
100%
Neurological Surgery
62%
Stem Cell Biology
90%
Translational Medicine
75%
Psychopharmacology
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Rutrick, D., D.J. Stein, G. Subramanian, B. Smith and M. Fava et al., 2017. Mavoglurant augmentation in OCD patients resistant to selective serotonin reuptake inhibitors: A proof-of-concept, randomized, placebo-controlled, phase 2 study. Adv. Ther., 34: 524-541.
    CrossRef  |  Direct Link  |  
  2. Trenkwalder, C., D. Berg, O. Rascol, K. Eggert and A. Ceballos-Baumann et al., 2016. A placebo-controlled trial of AQW051 in patients with moderate to severe levodopa-induced dyskinesia. Movement Disord., 31: 1049-1054.
    CrossRef  |  Direct Link  |  
  3. Crutcher, E., M. Ali, J. Harrison, J. Sovago, B. Gomez-Mancilla and C.P. Schaaf, 2016. Assessment of cognitive outcome measures in teenagers with 15q13.3 microdeletion syndrome. J. Autism Dev. Disord., 46: 1455-1463.
    CrossRef  |  Direct Link  |  
  4. Brykczynska, U., E. Pecho-Vrieseling, A. Thiemeyer, J. Klein and I. Fruh et al., 2016. CGG repeat-induced FMR1 silencing depends on the expansion size in human iPSCs and neurons carrying unmethylated full mutations. Stem Cell Rep., 7: 1059-1071.
    CrossRef  |  Direct Link  |  
  5. Brasa, S., A. Mueller, S. Jacquemont, F. Hahne and I. Rozenberg et al., 2016. Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome. Clin. Epigenet., Vol. 8. 10.1186/s13148-016-0181-x.
    CrossRef  |  Direct Link  |  
  6. Barch, D.M., S.R. Marder, M.P. Harms, L.F. Jarskog and R.W. Buchanan et al., 2016. Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial. Progr. Neuro-Psychopharmacol. Biol. Psychiatry, 71: 66-75.
    CrossRef  |  Direct Link  |  
  7. Reilmann, R., M.L. Rouzade-Dominguez, C. Saft, S.D. Sussmuth and J. Priller et al., 2015. A randomized, placebo‐controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Movement Disord., 30: 427-431.
    CrossRef  |  Direct Link  |  
  8. Kaufmann, M., A. Schuffenhauer, I. Fruh, J. Klein and A. Thiemeyer et al., 2015. High-throughput screening using iPSC-derived neuronal progenitors to identify compounds counteracting epigenetic gene silencing in fragile X syndrome. J. Biomol. Screen., 20: 1101-1111.
    CrossRef  |  Direct Link  |  
  9. Gulyas, B., J. Sovago, B. Gomez-Mancilla, Z. Jia and C. Szigeti et al., 2015. Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: A preliminary investigation in the postmortem human brain. Brain Struct. Funct., 220: 3043-3051.
    CrossRef  |  Direct Link  |  
  10. DeLorenzo, C., J. Sovago, J. Gardus, J. Xu and J. Yang et al., 2015. Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [11C]ABP688. Transl. Psychiatry, Vol. 5. 10.1038/tp.2015.189.
    CrossRef  |  Direct Link  |  
  11. Verpelli, C., I. Galimberti, B. Gomez‐Mancilla and C. Sala, 2014. Molecular basis for prospective pharmacological treatment strategies in intellectual disability syndromes. Dev. Neurobiol., 74: 197-206.
    CrossRef  |  Direct Link  |  
  12. Rascol, O., S. Fox, F. Gasparini, C. Kenney, T. Di Paolo and B. Gomez-Mancilla, 2014. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism Relat. Disord., 20: 947-956.
    CrossRef  |  Direct Link  |  
  13. Pop, A.S., B. Gomez-Mancilla, G. Neri, R. Willemsen and F. Gasparini, 2014. Fragile X syndrome: A preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development. Psychopharmacology, 231: 1217-1226.
    CrossRef  |  Direct Link  |  
  14. Kariuki-Nyuthe, C., B. Gomez-Mancilla and D.J. Stein, 2014. Obsessive compulsive disorder and the glutamatergic system. Curr. Opin. Psychiatry, 27: 32-37.
    CrossRef  |  Direct Link  |  
  15. Jacquemont, S., E. Berry-Kravis, R. Hagerman, F. von Raison and F. Gasparini et al., 2014. The challenges of clinical trials in fragile X syndrome. Psychopharmacology, 231: 1237-1250.
    CrossRef  |  Direct Link  |  
  16. Hagerman, R.J., V. Des-Portes, F. Gasparini, S. Jacquemont and B. Gomez-Mancilla, 2014. Translating molecular advances in fragile X syndrome into therapy: A review. J. Clin. Psychiatry, 75: e294-e307.
    CrossRef  |  PubMed  |  Direct Link  |  
  17. Gomez-Mancilla, B., R. Brand, T.P. Jurgens, H. Gobel and C. Sommer et al., 2014. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia, 34: 103-113.
    CrossRef  |  Direct Link  |  
  18. Gomez-Mancilla, B., E. Berry-Kravis, R. Hagerman, F. von Raison and G. Apostol et al., 2014. Development of mavoglurant and its potential for the treatment of fragile X syndrome. Expert Opin. Invest. Drugs, 23: 125-134.
    CrossRef  |  Direct Link  |  
  19. Di Paolo, T., L. Gregoire, D. Feuerbach, W. Elbast, M. Weiss and B. Gomez-Mancilla, 2014. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces L-Dopa-induced dyskinesias and extends the duration of L-Dopa effects in Parkinsonian monkeys. Parkinsonism Relat. Disord., 20: 1119-1123.
    CrossRef  |  Direct Link  |  
  20. Morin, N., M. Morissette, L. Gregoire, B. Gomez-Mancilla, F. Gasparini and T. Di Paolo, 2013. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated Parkinsonian monkeys. Neuropharmacology, 73: 216-231.
    CrossRef  |  Direct Link  |  
  21. Morin, N., L. Gregoire, M. Morissette, S. Desrayaud, B. Gomez-Mancilla, F. Gasparini and T. Di Paolo, 2013. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates. Neuropharmacology, 66: 355-364.
    CrossRef  |  Direct Link  |  
  22. Hefti, K., S.C. Holst, J. Sovago, V. Bachmann and A. Buck et al., 2013. Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep. Biol. Psychiatry, 73: 161-168.
    CrossRef  |  Direct Link  |  
  23. Gasparini, F., T. Di Paolo and B. Gomez-Mancilla, 2013. Metabotropic glutamate receptors for Parkinson's disease therapy. Parkinson's Dis. 10.1155/2013/196028.
    CrossRef  |  Direct Link  |  
  24. Gantois, I., A.S. Pop, C.E. de Esch, R.A. Buijsen and T. Pooters et al., 2013. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behav. Brain Res., 239: 72-79.
    CrossRef  |  Direct Link  |  
  25. Akkus, F., S.M. Ametamey, V. Treyer, C. Burger and A. Johayem et al., 2013. Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography. Proc. Natl. Acad. Sci. USA., 110: 737-742.
    CrossRef  |  Direct Link  |  
  26. Tabolacci, E., F. Pirozzi, B. Gomez-Mancilla, F. Gasparini and G. Neri, 2012. The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro. BMC Med. Genet., Vol. 13. 10.1186/1471-2350-13-13.
    CrossRef  |  Direct Link  |  
  27. Streffer, J.R., I.D. Grachev, C. Fitzer-Attas, B. Gomez-Mancilla and B. Boroojerdi et al., 2012. Prerequisites to launch neuroprotective trials in Parkinson's disease: An industry perspective. Movement Disord., 27: 651-655.
    CrossRef  |  Direct Link  |  
  28. Sepulveda-Falla, D., J. Matschke, C. Bernreuther, C. Hagel and B. Puig et al., 2011. Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer's disease. Brain Pathol., 21: 452-463.
    CrossRef  |  Direct Link  |  
  29. Ouattara, B., L. Gregoire, M. Morissette, F. Gasparini and I. Vranesic et al., 2011. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol. Aging, 32: 1286-1295.
    CrossRef  |  Direct Link  |  
  30. Gregoire, L., N. Morin, B. Ouattara, F. Gasparini and G. Bilbe et al., 2011. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat. Disord., 17: 270-276.
    CrossRef  |  Direct Link  |  
  31. Brockmann, K., A. Groger, A. Di Santo, I. Liepelt and C. Schulte et al., 2011. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Movement Disord., 26: 2335-2342.
    CrossRef  |  Direct Link  |  
  32. Berg, D., J. Godau, C. Trenkwalder, K. Eggert and I. Csoti et al., 2011. AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials. Movement Disord., 26: 1243-1250.
    CrossRef  |  Direct Link  |  
  33. Ouattara, B., F. Gasparini, M. Morissette, L. Gregoire, P. Samadi, B. Gomez‐Mancilla and T. Di Paolo, 2010. Effect of l‐Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. J. Neurochem., 113: 715-724.
    CrossRef  |  Direct Link  |  
  34. Ouattara, B., D. Hoyer, L. Gregoire, M. Morissette, F. Gasparini, B. Gomez-Mancilla and T. Di Paolo, 2010. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience, 167: 1160-1167.
    CrossRef  |  Direct Link  |  
  35. Morin, N., L. Gregoire, B. Gomez-Mancilla, F. Gasparini and T. Di Paolo, 2010. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology, 58: 981-986.
    CrossRef  |  Direct Link  |  
  36. Baumann, T.P., H. Duyar, M. Sollberger, J. Kuhle and A. Regeniter et al., 2010. CSF-tau and CSF-Aβ1-42 in posterior cortical atrophy. Dementia Geriatric Cognitive Disorders, 29: 530-533.
    CrossRef  |  Direct Link  |  
  37. Guerreiro, N., M. Staufenbiel and B. Gomez-Mancilla, 2008. Proteomic 2-D DIGE profiling of APP23 transgenic mice brain from pre-plaque and plaque phenotypes. J. Alzheimer's Dis., 13: 17-30.
    CrossRef  |  Direct Link  |  
  38. Gasparini, F., G. Bilbe, B. Gomez-Mancilla and W. Spooren, 2008. mGluR5 antagonists: Discovery, characterization and drug development. Curr. Opin. Drug Discovery Dev., 11: 655-665.
    Direct Link  |  
  39. Guerreiro, N., B. Gomez-Mancilla and S. Charmont, 2006. Optimization and evaluation of surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry for protein profiling of cerebrospinal fluid. Proteome Sci., Vol. 4. 10.1186/1477-5956-4-7.
    CrossRef  |  
  40. Gomez-Mancilla, B., E. Marrer, J. Kehren, A. Kinnunen and G. Imbert et al., 2005. Central nervous system drug development: An integrative biomarker approach toward individualized medicine. NeuroRx, 2: 683-695.
    CrossRef  |  Direct Link  |  
  41. Lesko, L.J., R.A. Salerno, B.B. Spear, D.C. Anderson and T. Anderson et al., 2003. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: Report of the first FDA‐PWG‐PhRMA‐DruSafe Workshop. J. Clin. Pharmacol., 43: 342-358.
    CrossRef  |  Direct Link  |  
  42. Rothermich, E.A., M.I. Brod, W.H. Schonfeld, C.R. Rowland and B. Gomez-Mancilla, 2002. Prospective study designs in outcomes research. Pharmacoeconomics, 20: 715-725.
    CrossRef  |  Direct Link  |  
  43. Anderson, D.C., B. Gomez-Mancilla, B.B. Spear, D.M. Barnes and K. Cheeseman et al., 2002. Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group. Pharm. J., 2: 284-292.
  44. Spierings, E.L., B. Gomez-Mancilla, D.E. Grosz, C.R. Rowland, F.S. Whaley and K.J. Jirgens, 2001. Oral almotriptan vs oral sumatriptan in the abortive treatment of migraine: A double-blind, randomized, parallel-group, optimum-dose comparison. Arch. Neurol., 58: 944-950.
    CrossRef  |  Direct Link  |  
  45. Gomez-Mancilla, B., N.R. Cutler, M.T. Leibowitz, E.L.H. Spierings and J.A. Klapper, 2001. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia, 21: 727-732.
    CrossRef  |  
  46. Colman, S.S., M.I. Brod, A. Krishnamurthy, C.R. Rowland, K.J. Jirgens and B. Gomez-Mancilla, 2001. Treatment satisfaction, functional status and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin. Therapeutics, 23: 127-145.
    CrossRef  |  Direct Link  |  
  47. Romach, M.K., E.M. Sellers, H.L. Kaplan, G.R. Somer and B. Gomez‐Mancilla, 2000. Efficacy of dexfenfluramine in the treatment of alcohol dependence. Alcoholism: Clin. Exp. Res., 24: 1534-1541.
    CrossRef  |  Direct Link  |  
  48. Busto, U.E., H.L. Kaplan, C.E. Wright, B. Gomez-Mancilla, L. Zawertailo, D.J. Greenblatt and E.M. Sellers, 2000. A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam and lorazepam. J. Clin. Psychopharmacol., 20: 628-635.
    Direct Link  |  
  49. Montplaisir, J., A. Nicolas, R. Denesle and B. Gomez-Mancilla, 1999. Restless legs syndrome improved by pramipexole A double-blind randomized trial. Neurology, 52: 938-938.
    CrossRef  |  Direct Link  |  
  50. Fleishaker, J.C., L.K. Pearson, D.W. Knuth, B. Gomez-Mancilla and S.F. Francom et al., 1999. Pharmacokinetics and tolerability of a novel 5-HT1D agonist, PNU-142633F. Int. J. Clin. Pharmacol. Ther., 37: 487-492.
    Direct Link  |  
  51. Bedard, P.J., P.J. Blanchet, D. Levesque, J.J. Soghomonian and R. Grondin et al., 1999. Pathophysiology of L-dopa-induced dyskinesias. Movement Disorders, 14: 4-8.
  52. Gagnon, C., B. Gomez-Mancilla, R. Markstein, P.J. Bedard and T. Di Paolo, 1995. Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors. Progr. Neuro-Psychopharmacol. Biol. Psychiatry, 19: 667-676.
    CrossRef  |  Direct Link  |  
  53. Blanchet, P.J., B. Gomez‐Mancilla, T. Paolo and P.J. Bedard, 1995. Is striatal dopaminergic receptor imbalance responsible for levodopa‐induced dyskinesia? Fundamental Clin. Pharmacol., 9: 434-442.
    CrossRef  |  Direct Link  |  
  54. Blanchet, P.J., B. Gomez-Mancilla and P.J. Bedard, 1994. DOPA-induced peak dose dyskinesia: Clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. J. Neural Trans. Suppl., 45: 103-112.
    Direct Link  |  
  55. Gomez‐Mancilla, B., R. Boucher, C. Gagnon, T. Di Paolo, R. Markstein and P.J. Bedard, 1993. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors. Movement Disorders, 8: 144-150.
    CrossRef  |  Direct Link  |  
  56. Gomez-Mancilla, B. and P.J. Bedard, 1993. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol., 16: 418-427.
    Direct Link  |  
  57. Gagnon, C., B. Gomez-Mancilla, P.J. Bedard and T. Di Paolo, 1993. Chronic CY 208–243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAa receptors. Neurosci. Lett., 163: 31-35.
    CrossRef  |  Direct Link  |  
  58. Bedard, P.J., B. Gomez-Mancilla, P. Blanchette, C. Gagnon, P. Falardeau and T. DiPaolo, 1993. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. Adv. Neurol., 60: 113-118.
  59. Pourcher, E., B. Gomez‐Mancilla and P.J. Bedard, 1992. Ethosuximide and tremor in Parkinson's disease: A pilot study. Movement Disorders, 7: 132-136.
    CrossRef  |  Direct Link  |  
  60. Gomez‐Mancilla, B., R. Boucher and P.J. Bedard, 1992. Effect of LY 171555 and CY 208‐243 on tremor suppression in the MPTP monkey model of parkinsonism. Movement Disorders, 7: 43-47.
    CrossRef  |  Direct Link  |  
  61. Gomez‐Mancilla, B., J.F. Latulippe, R. Boucher and P.J. Bedard, 1992. Effect of ethosuximide on rest tremor in the MPTP monkey model. Movement Disorders, 7: 137-141.
    CrossRef  |  Direct Link  |  
  62. Gomez-Mancilla, B. and P.J. Bedard, 1992. Effect of estrogen and progesterone on L-dopa induced dyskinesia in MPTP-treated monkeys. Neurosci. Lett., 135: 129-132.
    CrossRef  |  Direct Link  |  
  63. Gomez-Mancilla, B. and P.J. Bedard, 1992. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp. Neurol., 117: 185-188.
    CrossRef  |  Direct Link  |  
  64. Gomez-Mancilla, B., R. Boucher and P.J. Bedard, 1991. Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism. Clin. Neuropharmacol., 14: 359-366.
  65. Gomez-Mancilla, B. and P.J. Bedard, 1991. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated monkeys. J. Pharmacol. Exp. Therapeutics, 259: 409-413.
    Direct Link  |